Mahamaya Lifesciences Ltd

Management changes

• Regularization as Independent Director for 3-year term from Aug 25, 2026; founder of SABC.
• Reappointed Independent Director for 3-year term from Dec 11, 2026; Chartered Accountant with 30 years' finance experience.
• Reappointed Independent Director for 3-year term from Dec 11, 2026; agricultural scientist.
• Redesignated as Chairman liable to retire by rotation from Nov 01, 2026; father of Prashant Krishnamurthy.
• Redesignated as Managing Director not liable to retire by rotation from Nov 01, 2026; son of Krishnamurthy Ganesan.

AGM Details

• Date and time: 29 September 2026, 11:00 A.M.; mode: VC/OAVM.
• Record date: 23 September 2026; shareholders on record: 671.
• Meeting attended by 3 promoters and 7 public via video.

Resolutions presented

• Resolution 1 — Ordinary: Adopt standalone and consolidated audited financial statements.
• Resolution 2 — Ordinary: Reappointment of Prashant Krishnamurthy by rotation.
• Resolution 3 — Special: Redesignate Krishnamurthy Ganesan as Executive Director & Chairman; remuneration revision.
• Resolution 4 — Special: Redesignate Prashant Krishnamurthy as Managing Director; remuneration revision.
• Resolution 5 — Special: Revision in remuneration of Lalitha Krishnamurthy, Whole-Time Director.
• Resolution 6 — Special: Re-appointment of Dr. Gopal Krishna Raju as Non-Executive Independent Director.
• Resolution 7 — Special: Re-appointment of Dr. Charudatta Digambar Mayee as Non-Executive Independent Director.
• Resolution 8 — Special: Regularization/appointment of Bhagirath Choudhary as Non-Executive Independent Director.
• Resolution 9 — Ordinary: Ratification of remuneration payable to Cost Auditor for FY 2026-27.

Voting Results

• Resolution 1: Passed; ordinary resolution.
• Resolution 2: Passed; ordinary resolution.
• Resolution 3: Passed; special resolution.
• Resolution 4: Passed; special resolution.
• Resolution 5: Passed; special resolution.
• Resolution 6: Passed; special resolution.
• Resolution 7: Passed; special resolution.
• Resolution 8: Passed; special resolution.
• Resolution 9: Passed; ordinary resolution.

Dividend

• No dividend proposed or declared.

Director Changes

• Redesignation of Krishnamurthy Ganesan as Executive Director & Chairman.
• Prashant Krishnamurthy redesignated as Managing Director.
• Lalitha Krishnamurthy remuneration as Whole-Time Director.
• Regularization/appointment of Bhagirath Choudhary as Non-Executive Independent Director.
• Re-appointments: Dr. Gopal Krishna Raju and Dr. Charudatta Digambar Mayee as Non-Executive Independent Directors.

Auditor Appointments

• Cost Auditor remuneration for FY 2026-27 ratified; no change to statutory auditor.

Material Related Party Transactions

• No material related party transactions approved.

Other Material Approvals

• Remuneration approvals and director appointments constitute other material approvals.

Additional notes

• Scrutinizer's report by HPN & Associates dated 29 Sept 2026; voting results consolidated.

AGM Details

• Date and time: 29 September 2026 at 11:00 A.M. (IST) via VC/OAVM.
• Chair: Mr. Krishnamurthy Ganesan.

Key Resolutions

• Adoption of Audited Financial Statements for the year ended 31 March 2026.
• Re-appointment of Prashant Krishnamurthy (retiring by rotation).
• Re-designation of Krishnamurthy Ganesan as Executive Director and Chairman; remuneration revised.
• Re-designation of Prashant Krishnamurthy as Managing Director; remuneration revised.
• Remuneration revision for Lalitha Krishnamurthy, Whole-time Director.
• Re-appointment of Dr Gopal Krishna Raju as non-executive independent director.
• Re-appointment of Dr Charudatta Digambar Mayee as non-exec independent director.
• Regularization and appointment of Bhagirath Choudhary as non-exec independent director.
• Ratification of remuneration payable to the cost auditor for FY 2026-27.

Voting Status

• Remote e-voting conducted Sep 26–28, 2026; AGM voting facility available.
• Results to be communicated to exchanges with Scrutinizer’s report; not disclosed in filing.

Auditors

• Remuneration for cost auditor for FY 2026-27 ratified.

Mahamaya Lifesciences Limited: Trading Window closed from Oct 01, 2026 until 48 hours after the declaration of Un-Audited Financial Results (Standalone and Consolidated) for the half year ended Sep 30, 2026.

Financial performance

• Revenue from operations ₹328.87 crore, up 24.5% YoY.
• EBITDA ₹34.26 crore; margin 10.42% (up from 9.72%).
• PAT ₹16.52 crore; YoY growth 29%.
• PBT ₹23.87 crore; PAT margin ~5.02%.
• Basic EPS ₹8.33 per share.
• Net worth ₹121.93 crore; cash ₹39.39 crore; debt‑to‑equity 0.74x.

IPO and capital structure

• IPO on BSE SME platform on 18 Nov 2025; Fresh issue 56,38,800 shares; OFS 5,40,000.
• Issue price ₹114; total issue size ₹70.44 crore.
• Fresh IPO proceeds ₹61.96 crore; utilised ₹29.17 crore; unutilised ₹32.79 crore.
• Paid‑up equity capital at ₹23.405 crore; authorized ₹25 crore.

Manufacturing expansion and capex

• Dahej facility capacity: 400 MT to 2000 MT p.a. by 2026.
• Phased capex for warehouse, expansion, and new technical plant; ₹3,570.23 lakh identified.
• Timeline extension approved; completion targeted FY2027-28.

Product portfolio and R&D

• Diversified portfolio: insecticides, fungicides, herbicides, bio-stimulants, PGRs, bio-fertilizers.
• In-house R&D; upcoming active-ingredient R&D facility; regulatory readiness across domestic/international markets.

Global footprint and growth strategy

• Operations and exports across domestic and international markets; UAE subsidiary for global expansion.
• Strategic priorities include product innovation, regulatory capability, and efficient manufacturing.

Governance and leadership changes

• Bhagirath Choudhary appointed Additional Independent Director (Aug 25, 2026).
• CFO Amarendra Mohapatra elevated effective Nov 1, 2026.
• Ganesan redesignated to Chairman; Prashant Krishnamurthy to Managing Director (Nov 1, 2026).

Audit, internal controls and risk

• Statutory auditors: N. Naresh & Co; internal auditors: Chandramouli & Associates.
• Secretarial auditor: HPN & Associates; robust internal financial controls in place.

Dividend, liquidity and capital allocation

• No dividend declared for FY2025-26.
• Post-IPO liquidity strengthened; extension approved for IPO fund deployment.

CSR and ESG

• CSR spend ₹10.19 lakh; CSR obligation ₹18.18 lakh; unspent ₹7.9997 lakh transferred to ICAR.
• CSR Committee chaired by MD; focus on health, education, and sustainable agriculture.

Subsidiaries and related party transactions

• Wholly owned UAE subsidiary Mahamaya Lifesciences FZE; AED 150,000 capital; balance to be remitted FY26-27.
• Related party disclosures include directors’ remuneration and other intragroup transactions at arm's length.

AGM Details

• AGM date/time/mode: 29 Sep 2026, 11:00 AM IST, via VC/OAVM.
• Record/cut-off for voting: 23 Sep 2026.

Ordinary Business

• Adopt standalone and consolidated audited financial statements for year ended 31 March 2026.
• Reappoint Prashant Krishnamurthy as Director by rotation.

Special Resolutions

• Redesignate Krishnamurthy Ganesan as Executive Director and Chairman; salary ₹1,00,00,000 with 15% increment.
• Redesignate Prashant Krishnamurthy as Managing Director for 5 years; salary ₹1,20,00,000; commission up to 0.25%.
• Revise Lalitha Krishnamurthy's remuneration to ₹75,00,000 per year, with 15% increments.
• Re-appoint Dr. Gopal Krishna Raju as Non-Executive Independent Director for 3 years from 11 Dec 2026.
• Re-appoint Dr. Charudatta Digambar Mayee as Non-Executive Independent Director for 3 years from 11 Dec 2026.
• Appoint Bhagirath Choudhary as Independent Director from 25 Aug 2026 for 3 years.
• Ratify remuneration of Cost Auditor ₹1,10,000 for FY 2026-27.

Appointment of Company Secretary / Compliance Officer

• Mr. Kush Mishra appointed Company Secretary and Compliance Officer (KMP), effective Aug 25, 2026.

Availability

• Investor Presentation for Aug 7, 2026 investor meet is available on the company's website.
• Presentation does not contain any unpublished price sensitive information.